Comparative evaluation of hypolipidemic activity of ezetimibe and atorvastatin in coronary artery disease patients.

Author(s): Chakradhar T.

Abstract

Statins are the first line drugs for the treatment of hypercholesterolemia patients. In the treatment of hyperlipidemia combination therapy has showed significant results. This study was conducted to find the efficacy of hypolipidemic drugs in cardiovascular diseases. 75 patients were included in the study. Randomly all the patients were divided in to three groups. Group-I (Ezetimibe 10mg/day), Group-II (Atorvastatin 10mg/day), Group-III (Ezetimibe 10mg/day+Atorvastatin 10mg/day) given for 4 weeks. Blood samples were collected from all the patients before and at the end of study to estimate lipid profile. Mono therapy with drugs decreased the lipid levels but combination therapy significantly showed 33.75% reduction in LDL-cholesterol level. Ezetimibe showed 21.9%, Atorvastation 31.54 reduction in LDL-cholesterol levels. There was significant reduction in other lipids and increase the HDL levels. Co-administration of Ezetimibe with statins shows significant results with less adverse effects. More studies required to find safety, efficacy of Ezetimibe with other hypolipidemic drugs.

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.